Jump Financial LLC Boosts Holdings in Cellebrite DI Ltd. $CLBT

Key Points

• Jump Financial LLC increased its stake in Cellebrite DI Ltd. by 46.8%, holding approximately 206,965 shares valued at around $4 million at the end of the reporting period.
• Several institutional investors, including the Teacher Retirement System of Texas and Bank of America Corp DE, have also made significant investments in Cellebrite DI, indicating strong institutional interest in the stock.
• Despite recent target price cuts from multiple brokerages, five analysts rate the stock as a "Buy", with an average price target of $22.40, reflecting a consensus positive outlook for the company.

Jump Financial LLC lifted its position in shares of Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 46.8% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 206,965 shares of the company's stock after purchasing an additional 65,965 shares during the quarter. Jump Financial LLC owned 0.09% of Cellebrite DI worth $4,021,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in CLBT. Assetmark Inc. acquired a new stake in shares of Cellebrite DI during the 1st quarter worth approximately $33,000. Catalyst Capital Advisors LLC acquired a new stake in shares of Cellebrite DI during the 1st quarter worth approximately $51,000. Gen Wealth Partners Inc acquired a new stake in shares of Cellebrite DI during the 4th quarter worth approximately $85,000. NewEdge Advisors LLC grew its stake in shares of Cellebrite DI by 600.7% during the 4th quarter. NewEdge Advisors LLC now owns 3,910 shares of the company's stock worth $86,000 after purchasing an additional 3,352 shares during the period. Finally, JT Stratford LLC purchased a new position in shares of Cellebrite DI during the 1st quarter worth $209,000. Institutional investors and hedge funds own 45.88% of the company's stock.

Cellebrite DI Price Performance

Shares of CLBT stock traded down $0.31 during trading hours on Friday, reaching $16.40. 1,961,581 shares of the stock were exchanged, compared to its average volume of 1,677,224. The business's fifty day moving average is $14.98 and its two-hundred day moving average is $17.27. Cellebrite DI Ltd. has a 12-month low of $13.10 and a 12-month high of $26.30. The firm has a market capitalization of $3.93 billion, a P/E ratio of -21.58, a P/E/G ratio of 2.99 and a beta of 1.27.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last released its earnings results on Thursday, August 14th. The company reported $0.12 earnings per share for the quarter, topping analysts' consensus estimates of $0.11 by $0.01. The firm had revenue of $113.28 million for the quarter, compared to analyst estimates of $112.33 million. Cellebrite DI had a negative net margin of 34.56% and a positive return on equity of 23.92%. The business's quarterly revenue was up 18.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.10 earnings per share. Cellebrite DI has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. As a group, equities research analysts predict that Cellebrite DI Ltd. will post 0.3 earnings per share for the current fiscal year.

Analysts Set New Price Targets

CLBT has been the topic of several research analyst reports. Lake Street Capital reduced their price objective on shares of Cellebrite DI from $24.00 to $22.00 and set a "buy" rating on the stock in a report on Friday, August 15th. JPMorgan Chase & Co. reduced their price objective on shares of Cellebrite DI from $29.00 to $25.00 and set an "overweight" rating on the stock in a report on Monday, May 12th. Needham & Company LLC lowered their price objective on shares of Cellebrite DI from $24.00 to $18.00 and set a "buy" rating for the company in a research note on Thursday, August 14th. Finally, Wall Street Zen raised shares of Cellebrite DI from a "hold" rating to a "buy" rating in a research note on Saturday, August 16th. Five analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus target price of $22.40.

Cellebrite DI Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.